auriclosene

Small moleculeexperimental

Clinical trial activity

9 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
8
Phase 3
1
Phase 4
0

Earliest trial started Oct 1, 2008 (NCT00781339)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(CS(=O)(=O)O)N(Cl)Cl
Mol. weight
222.09 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • al-46383a
  • al-46383a
  • auriclosene
  • auriclosene
  • auriclosene
  • cd07223
  • nvc-422
  • nvc-422
  • sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02130518Phase 2Sep 1, 2014NovaBay Pharmaceuticals
NCT01877694Phase 2Jun 1, 2013NovaBay Pharmaceuticals
NCT01670032Phase 2/Phase 3 (Phase 3)Aug 1, 2012NovaBay Pharmaceuticals
NCT01532336Phase 2May 1, 2012NovaBay Pharmaceuticals
NCT01243125Phase 2Nov 1, 2010NovaBay Pharmaceuticals
NCT01106807Phase 2Apr 1, 2010Galderma
NCT01367314Phase 2Aug 1, 2009Hospital Infantil Dr. Robert Reid Cabral, NovaBay Pharmaceuticals, Novum Pharmaceutical Research Services
NCT00901693Phase 2Jun 1, 2009Alcon
NCT00781339Phase 2Oct 1, 2008Baylor University, NovaBay Pharmaceuticals
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovaBay PharmaceuticalsFor profit7722008
AlconFor profit1112009
Baylor UniversityAcademic/Hospital1012008
GaldermaFor profit1112010
Hospital Infantil Dr. Robert Reid CabralAcademic/Hospital1012009
Novum Pharmaceutical Research ServicesFor profit1012009
6 organizations
Page 1 / 1